Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HR2- patients with advanced or metastatic breast cancer: a systematic review and network meta-analysis.

IF 3.4 2区医学 Q2 ONCOLOGY

BMC Cancer Pub Date : 2025-10-09 DOI:10.1186/s12885-025-14841-2

Yuan Liu, Tongtong Ren, Xu Chen, Qinglan He, Xinchun Wang, Lisha Tang

引用次数: 0

Abstract Image

查看原文本刊更多论文

CDK4/6抑制剂联合内分泌治疗对HR+/HR2-晚期或转移性乳腺癌患者的比较疗效和安全性：系统评价和网络荟萃分析

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Cancer 医学-肿瘤学

CiteScore

6.00

自引率

2.60%

发文量

1204

审稿时长

6.8 months

期刊介绍： BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.